Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3082 plus mFOLFIRINOX or NALIRIFOX for first-line KRAS G12D-mutant metastatic pancreatic adenocarcinoma
CTR20262630Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Apr 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of setidegrasib in pancreatic adenocarcinoma (PDAC), sponsored by Astellas Pharma. Started Apr 2026; status: active.
02
Drugs
setidegrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20262630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262630.